ASCO 2022 | ​​NRG-HN002: Translational analysis of plasma tumor tissue modified viral HPV DNA and outcomes

Sue S. Yom, MD, PhD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses results from a translational analysis from NRG-HN002 (NCT02254278) evaluating the association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome. Blood samples to be analysed were taken from patients at three points during the trial – at baseline, 2 weeks into treatment, and 2-4 weeks post-treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.